{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:08:16Z","timestamp":1780466896883,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The ASC4OPT non-comparative phase 3b study (NCT04948333) evaluates asciminib once daily (QD) or twice daily (BID) in chronic myeloid leukemia in chronic phase (CML-CP) treated with \u22652 tyrosine kinase inhibitors (TKIs). This study enrolled 169 patients not in major molecular response (MMR), with unsatisfactory response (intolerant, warning or failure) as defined by European LeukemiaNet (ELN) 2020 criteria. Patients intolerant to their most recent TKI and in MMR at baseline (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200930) were also enrolled. The primary endpoint was the MMR rate at Week 48 for patients not in MMR at baseline. Results showed an overall MMR rate of 39.4% at Week 48 (40\u2009mg BID, 43.4%; 80\u2009mg QD, 35.4%) and 43.6% at Week 96 (40\u2009mg BID, 45.8%; 80\u2009mg QD, 41.5%) in patients not in MMR at baseline. Among 40 patients who had their asciminib dose escalated to 200\u2009mg QD, 17.5% were in MMR at Week 96. Most patients in MMR at baseline remained in MMR at 48 and 96 weeks (93.3% and 86.7%, respectively). Safety for both dosing regimens was consistent with that of previous studies. Findings support asciminib as a potential standard of care for patients with CML-CP who have not responded optimally to prior TKI therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-02965-8","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:35:48Z","timestamp":1776933348000},"page":"1296-1305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-4911","authenticated-orcid":false,"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-1050","authenticated-orcid":false,"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Dung","family":"Phu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Marco de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Ayala Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Abi Rached","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6947-1535","authenticated-orcid":false,"given":"Himanshu","family":"Pokhriyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin","family":"IC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schuld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pilipovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Alisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Maria","family":"Boquimpani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"2965_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"2965_CR2","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120\u201335.","journal-title":"J Med Chem"},{"key":"2965_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.","journal-title":"Leuk Res"},{"key":"2965_CR4","unstructured":"FDA. Scemblix [prescribing information]. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215358s012lbl.pdf. Accessed April 2026."},{"key":"2965_CR5","unstructured":"European Medicines Agency. Scemblix [Summary of Product Characteristics]. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/scemblix-epar-product-information_en.pdf. Accessed April 2026."},{"key":"2965_CR6","unstructured":"Swiss Public Assessment Report, Scemblix (asciminib). Available from: https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/zulassung\/swisspar\/68441-scemblix-20220808.pdf.download.pdf\/SwissPAR_Scemblix_final.pdf."},{"key":"2965_CR7","unstructured":"European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/scemblix. Accessed April 2026."},{"key":"2965_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"2965_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617\u201326.","journal-title":"Leukemia"},{"key":"2965_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2965_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2965_CR12","doi-asserted-by":"publisher","first-page":"E206","DOI":"10.1002\/ajh.23816","volume":"89","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2014","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, et al. Do chronic myeloid leukemia patients with late \u201cwarning\u201d responses benefit from \u201cwatch and wait\u201d or switching therapy to a second-generation tyrosine kinase inhibitor? Am J Hematol. 2014;89:E206\u201311.","journal-title":"Am J Hematol"},{"key":"2965_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjh.13936","volume":"173","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonz\u00e1lez G, et al. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016;173:114\u201326.","journal-title":"Br J Haematol"},{"key":"2965_CR14","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1016\/j.clml.2019.03.028","volume":"19","author":"T Soysal","year":"2019","unstructured":"Soysal T, Eskazan AE, Serin I, Sadri S, Keskin D, Ozgur Yurttas N, et al. The outcomes of chronic myeloid leukemia patients with molecular warning responses during imatinib treatment according to the European LeukemiaNet 2013 recommendations. Clin Lymphoma Myeloma Leuk. 2019;19:e377\u201384.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2965_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2556506","volume":"30","author":"E Atallah","year":"2025","unstructured":"Atallah E, Broder MS, Chan O, Flynn KE, Gilreath JA, Hine M, et al. Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase. Hematology. 2025;30:2556506.","journal-title":"Hematology"},{"key":"2965_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-143303","volume":"136","author":"KL Schoenbeck","year":"2020","unstructured":"Schoenbeck KL, Tummala S, Olin RL, Goyal NG, Dhruva A, Damon LE, et al. Excellent outcomes achieved with medical management of chronic phase CML patients with non-hematologic TKI intolerance. Blood. 2020;136:41\u20132.","journal-title":"Blood"},{"key":"2965_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106674","volume":"111","author":"CE Ma","year":"2021","unstructured":"Ma CE, Ghosh S, Leyshon C, Blosser N, Dersch-Mills D, Jupp J, et al. Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI. Leuk Res. 2021;111:106674.","journal-title":"Leuk Res"},{"key":"2965_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","volume":"38","author":"S Claudiani","year":"2024","unstructured":"Claudiani S, Chughtai F, Khan A, Hayden C, Fernando F, Khorashad J, et al. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance. Leukemia. 2024;38:796\u2013802.","journal-title":"Leukemia"},{"key":"2965_CR19","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med"},{"key":"2965_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","volume":"61","author":"YF Li","year":"2022","unstructured":"Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet. 2022;61:1393\u2013403.","journal-title":"Clin Pharmacokinet"},{"key":"2965_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s40262-024-01411-1","volume":"63","author":"FP Combes","year":"2024","unstructured":"Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, et al. Does justification for asciminib exist in patients with Philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation? Clin Pharmacokinet. 2024;63:1301\u201312.","journal-title":"Clin Pharmacokinet"},{"key":"2965_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885\u201398.","journal-title":"N Engl J Med"},{"key":"2965_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","volume":"20","author":"T Hughes","year":"2006","unstructured":"Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006;20:29\u201341.","journal-title":"Blood Rev"},{"key":"2965_CR24","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","volume":"37","author":"D R\u00e9a","year":"2023","unstructured":"R\u00e9a D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, et al. Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 2023;37:1060\u20137.","journal-title":"Leukemia"},{"key":"2965_CR25","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood"},{"key":"2965_CR26","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042\u201350.","journal-title":"Blood"},{"key":"2965_CR27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"2965_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2021-152561","volume":"138","author":"MJ Mauro","year":"2021","unstructured":"Mauro MJ, Minami Y, Rea D, Hochhaus A, Lomaia E, Voloshin S, et al. Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, Vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: update after 48 weeks. Blood. 2021;138:310.","journal-title":"Blood"},{"key":"2965_CR29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37:1048\u201359.","journal-title":"Leukemia"},{"key":"2965_CR30","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758\u201365.","journal-title":"Blood"},{"key":"2965_CR31","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1182\/blood-2023-178790","volume":"142","author":"J Cortes","year":"2023","unstructured":"Cortes J, Deininger M, Lomaia E, Moiraghi B, Undurraga S, Pavlovsky C, et al. Long-term results from the optic trial: a dose-optimization study of 3 starting doses of ponatinib. Blood. 2023;142:3164.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02965-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02965-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02965-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:43:22Z","timestamp":1780465402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02965-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2965"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02965-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AH: honoraria from Novartis (institutional), Incyte (institutional); consulting or advisory role for Novartis, Incyte; research funding from Bristol Myers Squibb (institutional), Enliven Therapeutics (institutional), Incyte (institutional), Novartis (institutional), Pfizer (institutional), Terns Pharmaceuticals\u00a0(institutional); travel, accommodationsand expenses from Johnson & Johnson, Novartis. PlC: honoraria from Incyte, Novartis. DM: honoraria from Ascentage Pharma, Incyte, Novartis, Pfizer; research funding from Incyte, Pfizer. DDHK: honoraria from Novartis, Sanofi; research funding from Novartis; participation in an advisory board meeting for Novartis, Sanofi. CP: honoraria from Novartis, Ascentage Pharma, Pfizer; participation in an advisory board meeting and speakers\u2019 bureau for Novartis; participation in speakers\u2019 bureau for BMS, Pint Pharma; participation in an advisory board meeting for Pfizer. FEN: consulting or advisory role for Novartis, Incyte Biosciences; membership of board of directors or advisory committees for Azurity Pharmaceuticals, GSK, Incyte, Novartis, Terns Pharmaceuticals; institutional research funding from Incyte Biosciences Europe, Novartis; participation in speakers\u2019 bureau for Incyte Biosciences, Novartis. BM: participation in speakers\u2019 bureau for Novartis, Pfizer and Takeda. GE: consulting or advisory role for Incyte, Novartis, Pfizer. FMdL: participation in an advisory board meeting and speakers\u2019 bureau for Novartis. RMAD: equity shareholder for Altum Sequencing Co; participation in speakers\u2019 bureau for GSK, BMS, Servier. MB: honoraria from AbbVie, AOP Health, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Incyte, Novartis, and Pfizer. CC: honoraria from Bristol-Myers Squibb, Chiltern International, Korea Otsuka Pharmaceutical, Novartis Oncology, and Pfizer. RAR, HP, AIC, PS, VP and FA: Novartis employment. CMB: membership on an entity\u2019s board of directors or advisory committees and participation in speakers\u2019 bureau for Janssen and Novartis; participation in speakers\u2019 bureau for Pint Pharma. SML, TN, SG, and\u00a0CDP FMdL have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}